Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Cash from Operations: 2009-2024

Historic Cash from Operations for Gyre Therapeutics (GYRE) over the last 16 years, with Dec 2024 value amounting to -$3.6 million.

  • Gyre Therapeutics' Cash from Operations rose 168.54% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year increase of 56.52%. This contributed to the annual value of -$3.6 million for FY2024, which is 114.06% down from last year.
  • Latest data reveals that Gyre Therapeutics reported Cash from Operations of -$3.6 million as of FY2024, which was down 114.06% from $25.9 million recorded in FY2023.
  • In the past 5 years, Gyre Therapeutics' Cash from Operations ranged from a high of $25.9 million in FY2023 and a low of -$83.8 million during FY2021.
  • Over the past 3 years, Gyre Therapeutics' median Cash from Operations value was $10.7 million (recorded in 2022), while the average stood at $11.0 million.
  • In the last 5 years, Gyre Therapeutics' Cash from Operations soared by 142.50% in 2023 and then plummeted by 114.06% in 2024.
  • Over the past 5 years, Gyre Therapeutics' Cash from Operations (Yearly) stood at -$55.0 million in 2020, then crashed by 52.15% to -$83.8 million in 2021, then soared by 112.75% to $10.7 million in 2022, then skyrocketed by 142.50% to $25.9 million in 2023, then tumbled by 114.06% to -$3.6 million in 2024.